Menu Search
Equities

Celyad Oncology SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1C0:MUN

Celyad Oncology SA

Actions
  • Price (EUR)0.288
  • Today's Change0.056 / 24.14%
  • Shares traded40.00
  • 1 Year change-37.39%
  • Beta1.2629
Data delayed at least 15 minutes, as of Feb 16 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

  • Revenue in EUR (TTM)186.00k
  • Net income in EUR-6.46m
  • Incorporated2007
  • Employees12.00
  • Location
    Celyad Oncology SARue Andre Dumont 9MONT-SAINT-GUIBERT 1435BelgiumBEL
  • Phone+32 10394100
  • Fax+32 10394141
  • Websitehttps://www.celyad.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.